The adipocytokine leptin is a key mediator of energy homeostasis. Recent papers have suggested that leptin may also have roles in the brain however it is unclear whether leptin is connected to symptoms of mental disorders. In this study, we sought to clarify the relationships between serum leptin level and psychopathology in schizophrenia (SZ) patients. The severity of positive symptoms inversely correlated with the serum leptin levels among SZ patients. There was no correlation between leptin levels and negative symptoms or neurocognition. Our data suggest a role of leptin in SZ positive symptoms.
Introduction
The adipocytokine leptin is thought to link reduced storage of energy to eating behavior (Ahima, 2008) . Thus, leptin is important in weight regulation and energy homeostasis. Leptin also activates its receptors in the brain limbic structures and may regulate brain functions beyond the limbic functions (Harvey, 2007) . However, conflicting results have been published so far on the relationship between cognition and serum leptin level (Gunstad et al., 2008; Holden et al., 2009; Beydoun et al., 2011) .
In patients with schizophrenia (SZ) treated with atypical antipsychotic medications, changes of serum leptin level and body weight are reportedly correlated (see reviews, Jin et al., 2008; Sentissi et al., 2008) . In addition to these observations, a positive correlation of changes in serum leptin level and improved overall psychopathology was also reported (Atmaca et al., 2003 (Atmaca et al., , 2007 . However, it is unclear whether serum leptin level correlates with specific subdomains of psychopathology, such as positive and negative symptoms, or cognitive performance. We address these questions by estimating the relationships of serum leptin level with * Corresponding author.
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severity of illness and psychopathology in SZ patients by using baseline data from the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) study. In the present study, we show possible roles of leptin in symptoms of SZ, especially those associated with positive symptoms. We also compare serum leptin levels between patients with antipsychotics and without any antipsychotics prior to the trial, in order to address potential effects of antipsychotics on serum leptin levels.
Materials and methods

The methods of the CATIE study
The CATIE study was to primarily assess the efficacy of atypical antipsychotics under the NIMH funding. The study was conducted between 2001 and 2004 at 57 clinical sites in the United States. Patients were randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone under double-blind conditions and followed for up to 18 months or until treatment was discontinued for any reason. Patients between18 and 65 years who received a Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnosis of SZ, based on the Structured Clinical Interview of the DSM-IV (SCID), were eligible to participate in this study. A wide spectrum of patients with
